Business
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey ha
About this update from Odyssey Therapeutics, Inc.
[{"type":"image","alt":"Odyssey Therapeutics Inc","displaySize":"","headline":null,"caption":"Odyssey Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/2559d742edf5c5ac716e167442ff340a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aRkPZHciz7QUlkYTLGVOlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/2559d742edf5c5ac716e167442ff340a","width":300,"height":80},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/aRkPZHciz7QUlkYTLGVOlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/2559d742edf5c5ac716e167442ff340a","width":300,"height":80}},"lazy":false},{"type":"text","content":"BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.","length":695,"tagName":"p"},{"type":"text","content":"In addition to the shares sold in the initial public offering described above, Odyssey announced a concurrent sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, at the initial public offering price of $18.00 per share, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.","length":366,"tagName":"p"},{"type":"text","content":"The gross proceeds to Odyssey from the initial public offering and concurrent private placement, without giving effect to the underwriters’ option to purchase additional shares in the initial public offering and before deducting underwriting discounts and commissions, placement agent fees and offering expenses payable by Odyssey, are expected to be approximately $304 million. All of the shares of common stock are being offered by Odyssey."...